Premium
Determination of the bioavailability of gentamicin to the lungs following inhalation from two jet nebulizers
Author(s) -
AlAmoud A. I.,
Clark B. J.,
Assi K. A.,
Chrystyn H.
Publication year - 2005
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/j.1365-2125.2005.02360.x
Subject(s) - bioavailability , gentamicin , inhalation , nebulizer , gentamicin sulfate , urine , pharmacology , chemistry , aminoglycoside , aerodynamic diameter , pharmacokinetics , excretion , medicine , antibiotics , anesthesia , aerosol , biochemistry , organic chemistry
Aims To determine the bioavailability of gentamicin to the lung following inhalation from two jet nebulizers. Methods Serial urine samples were obtained from 10 volunteers after a 80 mg dose given orally, nebulized from a Pari LC + (PARI) and MicroNeb III (MN) devices, or after a 40 mg intravenous dose. In vitro aerodynamic characteristics of the nebulized doses were also determined. Results The mean (SD) absolute gentamicin lung bioavailalibility following delivery by PARI and MN devices was 1.4 (0.4) and 1.7 (0.5) %. The mass median aerodynamic diameter (MMAD) of the drug particles from the PARI and MN systems was 8.6 (0.6) and 6.7 (0.5) µm and the corresponding fine particle doses (FPD) were 10.2 (2.8) and 11.7 (1.5) mg. Conclusions The MMAD and FPD data reflect the poor lung deposition of gentamicin identified by urinary excretion.